The FDA granted regenerative medicine advanced therapy designation to ALLO-501, a chimeric antigen receptor T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma.
ALLO-501 (Allogene Therapeutics) is an allogeneic CAR-T derived from induced pluripotent stem cells from healthy donors that are genetically modified using transcription activator-like effector nucleases (TALEN) gene-editing technology.
The investigational cell therapy is being evaluated as part of the ALPHA2 study in combination with ALLO-647 (Allogene Therapeutics) — CD52-directed